Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections.

Pharmacology research & perspectives - 1 Dec 2020

Chuwongwattana Sumonrat, Jantararoungtong Thawinee, Prommas Santirat, Medhasi Sadeep, Puangpetch Apichaya, Sukasem Chonlaphat

Abstract excerpt

Voriconazole is the first-line antifungal choice in the treatment of invasive fungal infections (IFIs). Single nucleotide polymorphisms (SNPs) in drug-metabolizing and transporter genes may affect voriconazole pharmacokinetics. This study aimed to determine the frequency of the CYP2C19 rs4244285, rs4986893, rs72552267, and rs12248560, CYP3A4 rs4646437, ABCB1 , and FMO3 alleles and determine the...

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antifungal Agents
Share to ATP Binding Cassette Transporter, Subfamily B
Share to Child, Preschool
Share to Cytochrome P-450 CYP2C19
Share to Cytochrome P-450 CYP3A
Share to Oxygenases
Share to Thailand
Share to Voriconazole

Source

Open in PubMed Open full text

Identifiers

PMID: 33124772
DOI: 10.1002/prp2.665
PMCID: PMC7596670

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections.PMID 33124772Read ↗

Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole.Semantic proximity Read ↗

Pharmacogenetic of voriconazole antifungal agent in pediatric patients.Semantic proximity Read ↗

Impact of CYP2C19, CYP2C9, CYP3A4, and FMO3 Genetic Polymorphisms and Sex on the Pharmacokinetics of Voriconazole after Single and Multiple Doses in Healthy Chinese Subjects.Semantic proximity Read ↗

Impact of CYP2C19 genotype on voriconazole exposure and effect of voriconazole on the activity of CYP3A in patients with haematological malignancies.Semantic proximity Read ↗

Interpersonal Factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 Genotypes Enough for Us to Make a Clinical Decision?Semantic proximity Read ↗

[CYP2C19 genetic polymorphism and monitoring voriconazole plasma concentrations in the treatment and prevention of invasive fungal disease for hematological patients].Semantic proximity Read ↗

Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infectionsSemantic proximity Read ↗

<i><scp>CYP</scp>2C19</i> Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?Semantic proximity Read ↗

Effects of CYP2C19, CYP2C9 and CYP3A4 gene polymorphisms on plasma voriconazole levels in Chinese pediatric patients.Semantic proximity Read ↗

The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: Systematic review and meta-analysis.Semantic proximity Read ↗

Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacySemantic proximity Read ↗

Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.